Profile data is unavailable for this security.
About the company
Strategic Partners A/S, formerly Orphazyme A/S, is a Denmark-based company active within the biopharmaceutical industry. It develops new therapies for the treatment of a family of genetic disorders. The Company's main focus is on preclinical development of medicines for the treatment of lysosomal storage diseases (LSDs), a group of approximately 50 genetic disorders that result from deficiencies of lysosomal enzymes or other lysosomal components, and protein aggregation diseases. The Company’s candidate, arimoclomol, stimulates the production of the cells’ protein rescue system, the heat shock proteins, which helps the misfolded proteins to either get back to their functional shape or, if this cannot be achieved, remove them from the cells by means of the cells’ recycling system, the lysosomes, so they no longer form toxic aggregates. The Company collaborates with academic institutions in Europe and the United States.
- Revenue in DKK (TTM)0.00
- Net income in DKK-11.42m
- Incorporated2009
- Employees1.00
- LocationStrategic Partners A/SLyskaer 8AKOEBENHAVN 2730DenmarkDNK
- Websitehttps://www.strategic-partners.dk/kontakt-os/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Respiratorius AB (publ) | 865.54k | -4.70m | 19.73m | -- | -- | 0.7721 | -- | 22.79 | -0.0229 | -0.0229 | 0.0042 | 0.078 | 0.0461 | -- | -- | -- | -24.98 | -- | -26.52 | -- | 63.66 | -- | -542.36 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -9.55 | -- |
| Stayble Therapeutics AB | 0.00 | -13.11m | 19.81m | 2.00 | -- | 2.52 | -- | -- | -0.6413 | -0.6413 | 0.00 | 0.2795 | 0.00 | -- | -- | 0.00 | -81.91 | -78.64 | -93.24 | -95.58 | -- | -- | -- | -- | -- | -- | 0.065 | -- | -- | -- | 3.22 | -- | -- | -- |
| Chosa Oncology AB | 3.21k | -5.51m | 26.08m | -- | -- | 1.87 | -- | 8,116.01 | -0.1745 | -0.1745 | 0.00009 | 0.3054 | 0.0002 | -- | 0.0009 | -- | -28.72 | -51.96 | -31.51 | -61.92 | -- | -- | -171,540.00 | -708.47 | -- | -28.22 | 0.00 | -- | -98.21 | -- | 28.33 | -- | -- | -- |
| Nidhogg Resources Holding AB (publ) | 20.57k | -2.71m | 27.05m | 3.00 | -- | 44.53 | -- | 1,315.23 | -0.0021 | -0.0021 | 0.00005 | 0.0005 | 0.0087 | -- | 0.0128 | 10,666.67 | -114.92 | -70.56 | -204.32 | -82.81 | -25,093.75 | -- | -13,156.25 | -- | -- | -- | -- | -- | -- | -- | 77.06 | -- | -- | -- |
| ATTANA AB | 2.66m | -8.83m | 27.68m | 10.00 | -- | 1.32 | -- | 10.41 | -0.021 | -0.021 | 0.0062 | 0.0151 | 0.1548 | -0.2965 | 2.45 | 413,469.00 | -51.41 | -37.18 | -85.49 | -46.66 | 124.64 | 175.97 | -332.16 | -254.69 | 0.0798 | -4.61 | 0.4351 | -- | -32.89 | 6.61 | 5.80 | -- | 8.21 | -- |
| PCI Biotech Holding ASA | 3.80m | -10.14m | 30.76m | 7.00 | -- | 1.52 | -- | 8.09 | -0.4287 | -0.4287 | 0.1607 | 0.8548 | 0.1334 | -- | 0.9365 | 857,000.00 | -35.59 | -36.44 | -40.42 | -40.14 | -- | -- | -266.74 | -1,055.43 | -- | -- | 0.0147 | -- | -37.05 | -20.78 | 63.13 | -- | -- | -- |
| Modus Therapeutics Holding AB | 0.00 | -9.64m | 31.41m | 2.00 | -- | 4.97 | -- | -- | -0.5898 | -0.5898 | 0.00 | 0.2738 | 0.00 | -- | -- | 0.00 | -165.57 | -141.06 | -- | -278.44 | -- | -- | -- | -- | -- | -18.39 | 0.00 | -- | -- | -- | 2.31 | -- | -- | -- |
| Combigene AB | 1.23m | -23.48m | 32.83m | 10.00 | -- | 0.5395 | -- | 26.69 | -1.84 | -1.84 | 0.0967 | 4.78 | 0.0161 | -- | 3.71 | 239,265.00 | -30.66 | -13.00 | -32.33 | -14.58 | -- | -- | -1,908.16 | -58.77 | -- | -- | 0.00 | -- | -79.23 | 268.58 | -479.27 | -- | -24.02 | -- |
| Ultimovacs ASA | 0.00 | -94.63m | 37.08m | 17.00 | -- | 0.3062 | -- | -- | -4.34 | -4.34 | 0.00 | 5.55 | 0.00 | -- | -- | 0.00 | -49.47 | -28.80 | -54.77 | -31.12 | -- | -- | -- | -- | -- | -334.05 | 0.0132 | -- | -- | -- | -12.78 | -- | -45.35 | -- |
| Strategic Partners A/S | 0.00 | -11.42m | 39.21m | 1.00 | -- | 2.06 | -- | -- | -325.75 | -325.75 | 0.00 | 455.65 | 0.00 | -- | -- | 0.00 | -42.26 | -76.08 | -50.77 | -105.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 32.00 | -- | -- | -- |
| Abera Bioscience AB | 0.00 | -4.90m | 42.73m | 6.00 | -- | 7.55 | -- | -- | -0.5213 | -0.5213 | 0.00 | 0.5733 | 0.00 | -- | -- | 0.00 | -73.37 | -79.42 | -98.59 | -96.10 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 13.74 | -- | -- | -- |
| Spago Nanomedical AB (publ) | 1.30m | -24.11m | 44.53m | 12.00 | -- | 1.69 | -- | 34.22 | -0.2119 | -0.2119 | 0.0086 | 0.1181 | 0.0525 | -- | 20.15 | 155,769.20 | -97.31 | -20.19 | -113.72 | -20.97 | -132.69 | -- | -1,852.59 | -4,853.45 | -- | -- | 0.00 | -- | 14.14 | -- | -7.72 | -- | -- | -- |
| Klaria Pharma Holding AB (publ) | -4.20m | -11.71m | 44.57m | 5.00 | -- | 2.99 | -- | -- | -0.1594 | -0.4121 | -0.0605 | 0.1603 | -0.0864 | -- | -- | -1,305,600.00 | -24.10 | -37.28 | -44.74 | -51.56 | -- | -- | -- | -2,077.34 | -- | -0.439 | 0.00 | -- | -100.00 | -- | 71.17 | -- | -- | -- |
| Dextech Medical AB | 0.00 | -3.17m | 48.95m | 1.00 | -- | 2.68 | -- | -- | -0.2665 | -0.2665 | 0.00 | 1.54 | 0.00 | -- | -- | 0.00 | -15.57 | -23.30 | -15.93 | -23.93 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.51 | -- | 18.92 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Danske Bank A/S (Investment Management)as of 31 Aug 2024 | 83.00 | 0.20% |
